Multi center study finds 'AIDS cocktail' therapy effective in advanced AIDS cases

July 03, 2001

Highly active anti-retroviral therapy (HAART), also known as "AIDS cocktail" therapy, is saving lives and preventing infections even in the most advanced AIDS patients, according to a new study.

The authors of a multi center study published in the July 3, 2001 issue of Annals of Internal Medicine calculated the exact reduction in death and opportunistic infections attributable to HAART. Researchers at 11 university medical centers across the country followed 528 advanced AIDS patients for an average of 15 months during the period from August 1995 through June 1999. The researchers found that HAART decreased the HIV death rate to 38 percent of pre-HAART levels, and decreased the rate of most opportunistic infections to 66 percent of pre-HAART levels.

"In general, other studies were based on healthier populations," said Edward Murphy, MD, MPH, professor of laboratory medicine at the University of California, San Francisco and principal investigator for the study at the UCSF site. "This study supports the clinical experience of doctors, that HAART does work in these advanced patients."

Patients entering the study had a median CD4+ lymphocyte count of 15. Healthy adults usually have CD4+ counts between 600 and 1,000. Patients with counts below 200 have severely suppressed immune systems. "Untreated, someone with a count of 10 or 20 has a life expectancy of about a year," said Murphy.

The study analyzed data from the Viral Activation Transfusion Study (VATS) which followed AIDS patients with anemia who also tested positive for cytomegalovirus (CMV), a herpes virus that is a common cause of opportunistic diseases in persons with AIDS. Researchers used VATS data because the study spanned the introduction of HAART. In January of 1996 only 1 percent of study participants were using HAART, but by January of 1999 that number rose to 79 percent. Because of the timing of the study, researchers were able to track the effects of HAART on individual patients. "Our study was able to determine each patient's HAART history," said Murphy. "Therefore, we could figure out more precisely what the benefit of HAART was."

Researchers also found that HAART decreased opportunistic infections (not including CMV) to 66 percent of pre-HAART levels, but HAART did not decrease instances of CMV disease.

HAART suppresses the replication of HIV particles in the blood stream, allowing a patient's immune system to recover. For this study, HAART was defined as use of at least three HIV antiretroviral medications, at least one of which was an HIV protease inhibitor or a non-nucleoside HIV reverse transcriptase inhibitor.
Co-investigators on the study include Edward Murphy, MD, MPH, UCSF; Ann Collier, MD, University of Washington; Leslie Kalish, ScD, New England Research Institute; Susan Assmann, PhD, New England Research Institute; Michael Para, MD, Ohio State University; Timothy Flanigan, MD, Brown University Medical School; Princy Kumar, MD, Georgetown University Medical Center; Letty Mintz, ANP, Mount Sinai Medical Center; Frances Wallach, MD, Mount Sinai Medical Center; and George Nemo, PhD, National Heart, Lung, and Blood Institute.

The study was funded by the National Heart, Lung and Blood Institute.

University of California - San Francisco

Related Aids Articles from Brightsurf:

Developing a new vaccination strategy against AIDS
Infection researchers from the German Primate Center (DPZ) -- Leibniz Institute for Primate Research have in cooperation with international colleagues tested a new vaccination strategy against the HIV-related simian immunodeficiency virus (SIV) in rhesus monkeys.

HIV-AIDS: Following your gut
Researchers find a way to reduce replication of the AIDS virus in the gastrointestinal tract.

A path toward ending AIDS in the US by 2025
Using prevention surveillance data to model rates of HIV incidence, prevalence and mortality, investigators at Brigham and Women's Hospital and Johns Hopkins Bloomberg School of Public Health set targets, specifically a decrease in new infections to 21,000 by 2020 and to 12,000 by 2025, that would mark a transition toward ending the HIV/AIDS epidemic.

What does it take for an AIDS virus to infect a person?
Researchers examined the characteristics of HIV-1 strains that were successful in traversing the genital mucosa that forms a boundary to entry by viruses and bacteria.

How AIDS conquered North America
A new technique that allowed researchers to analyze genetic material from serum samples of HIV patients taken before AIDS was known provides a glimpse of unprecedented detail into the beginnings of the AIDS epidemic in North America.

New research could help build better hearing aids
Scientists at Binghamton University, State University of New York want to improve sensor technology critical to billions of devices made every year.

NY State Department of Health AIDS Institute funds HIV/AIDS prevention in high-risk youth
NewYork-Presbyterian's Comprehensive Health Program and Project STAY, an initiative of the Harlem Heath Promotion Center (HHPC) at Columbia University's Mailman School of Public Health has received two grants totaling more than $3.75 million from the New York State Department of Health AIDS Institute for their continued efforts to prevent HIV/AIDS in at-risk youth.

A new way to nip AIDS in the bud
When new HIV particles bud from an infected cell, the enzyme protease activates to help the viruses infect more cells.

AIDS research prize for Warwick academic
A researcher at the University of Warwick has received international recognition for his contribution to AIDS research.

Insects inspire next generation of hearing aids
An insect-inspired microphone that can tackle the problem of locating sounds and eliminate background noise is set to revolutionize modern-day hearing aid systems.

Read More: Aids News and Aids Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to